stockportfolio.pro
Candel Therapeutics, Inc. (CADL)
Healthcare · Biotechnology · NasdaqGM
Candel Therapeutics, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $125,000 | $125,000 | $125,000 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-17.68M | $-36.12M | $-18.79M | $-37.94M | $-55.18M | $-38.18M |
| Net margin | -14144.0% | -28899.2% | -15035.2% | — | — | — |
Source: Candel Therapeutics, Inc. SEC filings (10-K).
Explore 6 years of Candel Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CADL in your portfolio →
Candel Therapeutics, Inc. financial history by metric
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Candel Therapeutics, Inc. — frequently asked questions
What is Candel Therapeutics, Inc.'s revenue?
Candel Therapeutics, Inc. (CADL) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Candel Therapeutics, Inc. profitable?
No — CADL reported a net loss of $-38.18M in fiscal 2025.
What is CADL's P/E ratio?
Candel Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Candel Therapeutics, Inc. have?
As of fiscal year 2025, CADL carried roughly $47.13M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Candel Therapeutics, Inc.'s market cap?
Candel Therapeutics, Inc. (CADL) has a market capitalization of about $612.54M, based on the latest data in our nightly-refreshed cache.
When does Candel Therapeutics, Inc.'s fiscal year end?
CADL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Candel Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.